Home / Market News / $UTHR
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

TD Cowen Maintains Buy Rating and Increases Price Target for United Therapeutics

Nov 5, 2026, 11:02 PM UTC · Primary ticker $UTHR

TD Cowen has reiterated its 'Buy' rating for United Therapeutics and increased its price target from $675 to $700. This adjustment suggests a potential 15.0% upside from the company's recent closing price, indicating a positive outlook from the analyst firm.

TD Cowen maintained its 'Buy' rating on United Therapeutics and raised its price target to $700 from $675. This 3.7% increase in the price target implies a 15.0% upside from the company's November 4, 2026, closing price of $608.49. This analyst action is a positive signal for United Therapeutics, suggesting that TD Cowen sees continued growth potential and undervaluation in the stock. For traders, this could lead to short-term positive momentum as investors react to the upgraded outlook, though the long-term impact depends on the company's actual performance and broader market conditions. The key opportunity lies in potential capital appreciation if the stock moves towards the new price target, while the risk is that the analyst's projection may not materialize.

$UTHR positive Price target increase and maintained buy rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.